-
NICE gives thumbs-down to Zeposia in England and Wales
NICE is the government agency that recommends which drugs should be provided to National Health Service patients in England and Wales. It’s just said no to Zeposia (ozanimod), claiming it’s not as cost-effective as Avonex (inteferon beta1-a) to treat MS.
Have you considered switching from Avonex to Zeposia? Should cost-effectiveness ever be a factor in the ability to have a medication prescribed?
Sorry, there were no replies found.
Log in to reply.